Future combination therapy preclinical studies should be conducted to design successful trials reflecting the full therapeutic potential of ET-1R antagonists in ovarian cancer treatment, targeting the miR-200/ZEB1 circuit. This evidence concerns the gene ZEB1 and ovarian carcinoma.